Tagrisso 40mg Tablet

Tagrisso (Osimertinib) is a medication used to treat non-small cell lung cancer (NSCLC) with specific epidermal growth factor receptor (EGFR) mutations. It is a third-generation EGFR tyrosine kinase inhibitor that binds irreversibly to mutated EGFR proteins, particularly those with common mutations such as L858R or exon 19 deletions.

Uses:

Tagrisso is indicated for the treatment of adults with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations. In June 2024, China approved the use of Tagrisso in combination with chemotherapy as a first-line treatment for this condition, based on clinical trials showing improved progression-free survival.

Dosage:

The recommended dosage of Tagrisso is 80 mg taken orally once daily, with or without food. It is important to follow the prescribing physician's instructions regarding dosage and duration of treatment.

Side Effects: Common side effects of Tagrisso include:

• Diarrhea
• Rash
• Dry skin
• Nail inflammation
• Stomatitis (inflammation of the mouth)
• Fatigue
• Cough
• Decreased appetite
• Low platelet counts
• Low white blood cell counts

Patients should inform their healthcare provider if they experience any severe or persistent side effects.

Precautions:

• Pregnancy: Tagrisso can cause fetal harm. Women of reproductive potential should use effective contraception during treatment and for six weeks after the final dose.
• Breastfeeding: It is not recommended to breastfeed during treatment with Tagrisso and for two weeks after the final dose.
• Drug Interactions: Tagrisso is metabolized by CYP3A4 and CYP3A5 enzymes. Co-administration with strong inhibitors or inducers of these enzymes may affect the efficacy and safety of Tagrisso.

Availability in India:

In India, Tagrisso is available in 40 mg and 80 mg tablet forms. The 80 mg tablet is marketed by AstraZeneca and contains Osimertinib (80 mg). 

Additional Information:

For more detailed information, including potential drug interactions and specific patient considerations, please refer to the prescribing information or consult a healthcare professional.